The novel anticoagulants: The surgeons' prospective

Fadi E. Shamoun; Elvis N. Martin; Samuel R. Money

doi:10.1016/j.surg.2012.09.016

The novel anticoagulants: The surgeons' prospective

Fadi E. Shamoun, Elvis N. Martin, Samuel R. Money

Cardiovascular Diseases

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.

Original language	English (US)
Pages (from-to)	303-307
Number of pages	5
Journal	Surgery (United States)
Volume	153
Issue number	3
DOIs	https://doi.org/10.1016/j.surg.2012.09.016
State	Published - Mar 2013

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.surg.2012.09.016

Cite this

@article{805bf360f2d14cb096267a4b182328be,

title = "The novel anticoagulants: The surgeons' prospective",

abstract = "Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.",

author = "Shamoun, {Fadi E.} and Martin, {Elvis N.} and Money, {Samuel R.}",

year = "2013",

month = mar,

doi = "10.1016/j.surg.2012.09.016",

language = "English (US)",

volume = "153",

pages = "303--307",

journal = "Surgery (United States)",

issn = "0039-6060",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - The novel anticoagulants

T2 - The surgeons' prospective

AU - Shamoun, Fadi E.

AU - Martin, Elvis N.

AU - Money, Samuel R.

PY - 2013/3

Y1 - 2013/3

N2 - Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.

AB - Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.

UR - http://www.scopus.com/inward/record.url?scp=84873997956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873997956&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2012.09.016

DO - 10.1016/j.surg.2012.09.016

M3 - Review article

C2 - 23218887

AN - SCOPUS:84873997956

SN - 0039-6060

VL - 153

SP - 303

EP - 307

JO - Surgery (United States)

JF - Surgery (United States)

IS - 3

ER -

The novel anticoagulants: The surgeons' prospective

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this